{
    "clinical_study": {
        "@rank": "77354", 
        "acronym": "CRATUS", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Experimental", 
                "description": "Group A (10 subjects) - Allogeneic human mesenchymal stem cells: 100 million cells/ml delivered via peripheral intravenous infusion."
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Experimental", 
                "description": "Group B (10 subjects) - Allogeneic human mesenchymal stem cells: 200 million cells/ml delivered via peripheral intravenous infusion."
            }, 
            {
                "arm_group_label": "Group C", 
                "arm_group_type": "Experimental", 
                "description": "Group C (10 subjects) - Placebo delivered via peripheral intravenous infusion."
            }
        ], 
        "brief_summary": {
            "textblock": "Before initiating the full randomized study, a Pilot Safety Phase will be performed. The\n      randomized portion of this trial will be conducted after a full review of the safety data\n      from the Pilot Phase by the Data safety monitoring board.\n\n      Following the Pilot Phase of fifteen (15) subjects, thirty (30) subjects are scheduled to\n      undergo infusion and meeting all inclusion/exclusion criteria will be evaluate at baseline."
        }, 
        "brief_title": "AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery.", 
        "condition": "Aging Frailty", 
        "detailed_description": {
            "textblock": "A Pilot Phase will be performed to test the safety of dose and volume escalation of cells\n      administered via peripheral intravenous infusion.  The randomized portion of the study will\n      be conducted after a full review of the safety data from the Pilot Phase by the data safety\n      monitoring board.\n\n      RANDOMIZATION STUDY\n\n      This Phase I/II, randomized, blinded, placebo-controlled study is designed to evaluate the\n      safety and tolerability of allogenic human mesenchymal stem cells in patients with Frailty\n      and to explore potential efficacy over 4 weeks.\n\n      Approximately fifteen (15) subjects will be enrolled in the pilot phase and thirty (30)\n      subjects with Frailty will be enrolled for a total of forty-five (45) subjects.  Subjects\n      will then be enrolled and randomized 1:1:1 to an active arm or placebo.  Additional subjects\n      may be enrolled if deemed appropriate.\n\n      Eligible subjects must have a diagnosis or symptoms of frailty as defined by the Canadian\n      Study on Health & Aging. Following informed consent before or at the screening visit, the\n      diagnosis of FRAILTY will be confirmed by investigator review of medical history."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Provide written informed consent.\n\n          -  Subjects age greater than or equal to 60 and less than or qual to 95 years at the\n             time of signing the Informed Consent Form.\n\n          -  Show signs of frailty apart from a concomitant condition as assessed by the\n             Investigator with a frailty score of 4 to 7 using the Clinical Frailty Scale\n\n        Exclusion Criteria:\n\n          -  Score of less than or equal to 24 on the Mini Mental State Examination (MMSE)\n\n          -  Inability to perform any of the assessments required for endpoint analysis (report\n             safety or tolerability concerns, perform pulmonary function tests, undergo blood\n             draws, read and respond to questionnaires.\n\n          -  Active listing (or expected future listing) for transplant of any organ.\n\n          -  Clinically important abnormal screening laboratory values, including but not limited\n             to: hemoglobin <8 g/dl, white blood cell count <3000/mm3, platelets<80,000/mm3,\n             international normalized ratio (INR) > 1.5, aspartate transaminase, alanine\n             transaminase, or alkaline phosphatase > 3 times upper limit of normal, total\n             bilirubin > 1.5 mg/dl.\n\n          -  Serious comorbid illness that, in the opinion of the investigator, may compromise the\n             safety or compliance of the patient or preclude successful completion of the study.\n             Including, but not limited to: HIV, advanced liver or renal failure, class III/IV\n             congestive heart failure, myocardial infarction, unstable angina, or cardiac\n             revascularization within the last six months, or  severe obstructive ventilatory\n             defect.\n\n          -  Any other condition that, in the opinion of the investigator, may compromise the\n             safety or compliance of the patient or preclude successful completion of the study.\n\n          -  Have known allergies to penicillin or streptomyocin. Be an organ transplant\n             recipient.\n\n          -  Have a clinical history of malignancy within 5 years (i.e., patients with prior\n             malignancy must be disease free for 5 years), except curatively-treated basal cell\n             carcinoma, squamous cell carcinoma, or cervical carcinoma.\n\n          -  Have a non-pulmonary condition that limits lifespan to < 1 year.\n\n          -  Have a history of drug or alcohol abuse within the past 24 months.\n\n          -  Be serum positive for HIV, hepatitis BsAg or Viremic hepatitis C.\n\n          -  Be currently participating (or participated within the previous 30 days) in an\n             investigational therapeutic or device trial.\n\n          -  Be a female who is pregnant, nursing, or of childbearing potential while not\n             practicing effective contraceptive methods. Female patients must undergo a blood or\n             urine pregnancy test at screening and within 36 hours prior to injection.\n\n          -  Female subjects must have an Follicle-stimulating hormone (FSH) < 25.8 IU/L\n\n          -  Have hypersensitivity to dimethyl sulfoxide (DMSO)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "95 Years", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "45", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 14, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02065245", 
            "org_study_id": "20130646"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Group A", 
                    "Group B"
                ], 
                "intervention_name": "Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Group C", 
                "intervention_name": "Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Aging Frailty, Frailty, Cardiovascular", 
        "lastchanged_date": "February 14, 2014", 
        "link": {
            "description": "Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine", 
            "url": "http://isci.med.miami.edu"
        }, 
        "location": {
            "contact": {
                "email": "jhare@med.miami.edu", 
                "last_name": "Joshua M Hare, MD", 
                "phone": "305-243-5579"
            }, 
            "contact_backup": {
                "email": "ddifede@med.miami.edu", 
                "last_name": "Darcy L DiFede, RN, BSN", 
                "phone": "305-243-9106"
            }, 
            "facility": {
                "address": {
                    "city": "Miami", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "33136"
                }, 
                "name": "ISCI/University of Miami Miller School of Medicine"
            }, 
            "investigator": [
                {
                    "last_name": "Joshua M Hare, MD", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Pascal Goldschmidt, MD", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase I/II, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Aging Frailty.", 
        "overall_contact": {
            "email": "jhare@med.miami.edu", 
            "last_name": "Joshua M Hare, MD", 
            "phone": "305-243-5579"
        }, 
        "overall_official": {
            "affiliation": "ISCI / University of Miami Miller School of Medicine", 
            "last_name": "Joshua M Hare, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Incidence (at one month post infusion) of any treatment-emergent serious adverse events (TE-SAEs), defined as the composite of: death, non-fatal pulmonary embolism, stroke, hospitalization for worsening dyspnea and clinically significant laboratory test abnormalities.\nSerum chemistry: sodium, potassium, chloride, bicarbonate, blood urea nitrogen, creatinine, glucose, calcium, phosphate, aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin (fractionate if total >1.5 times normal), alkaline phosphatase, \u03b3-glutamyl transaminase (GGT), albumin,\nHematology (Complete blood count): hemoglobin, hematocrit, platelets, white blood cells (WBC), WBC differential", 
            "measure": "Incidence of any treatment emergent serious adverse events (TE-SAEs)", 
            "safety_issue": "Yes", 
            "time_frame": "One Month post infusion"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02065245"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Miami", 
            "investigator_full_name": "Joshua M Hare", 
            "investigator_title": "Chief Science Officer / ISCI Director / Senior Associate Dean", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "\u2022 Difference in rate of decline of Frailty defined as:\nReduced Activity\nSlowing of Mobility\nWeight Loss\nDiminished handgrip strength\nExhaustion", 
                "measure": "Difference in rate of decline of Frailty", 
                "safety_issue": "No", 
                "time_frame": "At baseline and 6 months."
            }, 
            {
                "description": "\u2022\tDifference in subject quality of life assessment(s):", 
                "measure": "Difference in subject quality of life assessment(s):", 
                "safety_issue": "No", 
                "time_frame": "At baseline and 6 months."
            }, 
            {
                "description": "Death from any cause.", 
                "measure": "Death from any cause", 
                "safety_issue": "No", 
                "time_frame": "At baseline and 6 months."
            }, 
            {
                "description": "Exercise change in ejection fraction.", 
                "measure": "Exercise change in ejection fraction.", 
                "safety_issue": "No", 
                "time_frame": "At baseline and 6 months."
            }, 
            {
                "description": "\u2022 The following panel of inflammatory markers:  C-reactive protein (CRP), Interleukin-6, D-dimer, fibrinogen, complete blood count with differential, DNA, cytomegalovirus, and TNF\u03b1", 
                "measure": "Inflammatory Markers.", 
                "safety_issue": "No", 
                "time_frame": "At Baseline and 6 months."
            }
        ], 
        "source": "University of Miami", 
        "sponsors": {
            "collaborator": {
                "agency": "The EMMES Corporation", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "University of Miami", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}